Abstract
The diagnostic accuracy of screening for bone metastases was evaluated using whole-body magnetic resonance imaging (WB-MRI) compared with combined fluorodeoxyglucose (FDG) positron emission tomography (PET) and computed tomography (CT) (FDG-PET-CT). In a prospective, blinded study, 30 consecutive patients (18 female, 12 male; 24–76 years) with different oncological diseases and suspected skeletal metastases underwent FDG-PET-CT as well as WB-MRI with the use of parallel imaging (PAT). With a 32-channel scanner, coronal imaging of the entire body and sagittal imaging of the complete spine was performed using T1-weighted and short tau inversion recovery (STIR) sequences in combination. PET-CT was conducted using a low-dose CT for attenuation correction, a PET-emission scan and diagnostic contrast-enhanced CT scan covering the thorax, abdomen and pelvis. Two radiologists read the MRI scans, another radiologist in combination with a nuclear medicine physician read the PET-CT scans, each in consensus. The standard of reference was constituted by radiological follow-up within at least 6 months. In 28 patients, 102 malignant and 25 benign bone lesions were detected and confirmed. WB-MRI showed a sensitivity of 94% (96/102), PET-CT exams achieved 78% (79/102; P<0.001). Specificities were 76% (19/25) for WB-MRI and 80% (20/25) for PET-CT (P>0.05). Diagnostic accuracy was 91% (115/127) and 78% (99/127; P<0.001), respectively. Cut-off size for the detection of malignant bone lesions was 2 mm for WB-MRI and 5 mm for PET-CT. WB-MRI revealed ten additional bone metastases due to the larger field of view. In conclusion, WB-MRI and FDG-PET-CT are robust imaging modalities for a systemic screening for metastatic bone disease. PAT allows WB-MRI bone marrow screening at high spatial resolution and with a diagnostic accuracy superior to PET-CT.
Similar content being viewed by others
References
Rubens RD (1998) Bone metastases: the clinical problem. Eur J Cancer 34:210–213
Edelstyn GA, Gillespie PJ, Grebbel FS (1967) The radiological demonstration of osseous metastases: experimental observations. Clin Radiol 18:158–162
Eustace S, Tello R, DeCarvalho V et al (1997) A comparison of whole-body turbo STIR MR imaging and planar 99 m TC-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. Am J Roentgenol 169:1655–1661
Cheran SK, Herndon JE, Patz EF (2003) Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung cancer 44:317–325
Even-Sapir E, Metser U, Flusser G, Zuriel L, Kollender Y, Lerman H (2004) Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 45:272–278
Pelosi E, Messa C, Sironi S, Picchio M, Landoni C, Bettinardi V et al (2004) Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 31:932–939
Vanel D, Dromain C, Tardivon A (2000) MRI of bone marrow disorders. Eur Radiol 10:224–229
Imamura F, Kuriyama K, Seto T, Hasegawa Y, Nakayama T, Nakamura S et al (2000) Detection of bone marrow metastases of small cell lung cancer with magnetic resonance imaging: early diagnosis before destruction of osseous structure and implications for staging. Lung Cancer 27:189–197
Daldrup-Link HE, Franzius C, Link TM et al (2001) Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. Am J Roentgenol 177:229–236
Steinborn M, Heuck AF, Tiling R, Bruegel M, Gauger L, Reiser MF (1999) Whole body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr 23:123–129
Iizuka-Mikami M, Nagai K, Yoshida K, Sugihara T, Suetsugu Y, Mikami M et al (2004) Detection of bone marrow and extramedullary involvement in patients with non-Hodgkin’s lymphoma by whole-body MRI: comparison with bone and 67Ga scintigraphies. Eur Radiol 14:1074–1081
Walker R, Kessar P, Blanchard R, Dimasi M, Harper K, DeCarvalho V et al (2000) Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: preliminary clinical experience. J Magn Reson Imaging 11:343–350
Mehta RC, Marks MP, Hinks RS, Glover GH, Enzmann DR (1995) MR evaluation of vertebral metatases: T1-weighted short inversion time inversion recovery, fast spin echo, and inversion-recovery fast spin-echo sequences. Am J Neuroradiol 16:281–288
Kellenberger CJ, Miller SF, Khan M, Gilday DL, Weitzman S, Babyn PS et al (2004) Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children. Eur Radiol 14:1829–1841
Mahnken A, Wildberger JE, Adam G, Stanzel S, Schmitz-Rode T, Günther R et al (2005) Is there a need for contrast-enhanced T1-weighted MRI of the spine after inconspicuous short τ inversion recovery imaging? Eur Radiol 15:1387–1392
Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R et al (2000) A combined PET-CT scanner for clinical oncology. J Nucl Med 42:1369–1379
Roemer PB, Edelstein WA, Hayes CE, Souza SP, Mueller OM (1990) The nmr phased array. Magn Reson Med 16:192–225
Sodickson DK, Manning WJ (1997) Simultaneous acquisition of spatial harmonics (SMASH): fast imaging with radiofrequency coil arrays. Magn Reson Med 38:591–603
Griswold MA, Jakob PM, Heidemann RM, Nittka M, Jellus V, Wang J et al (2002) Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med 47:1202–1210
Zech CJ, Hermann KA, Huber A, Dietrich O, Stremmer A, Herzog P et al (2004) High resolution MR imaging of the liver with T2-weighted sequences using integrated parallel imaging: comparison of prospective motion correction and respiratory triggering. J Magn Reson Imaging 20:443–450
Brix G, Lechel U, Glatting G, Ziegler SI, Muenzing W, Mueller SP et al (2005) Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG-PET/CT examinations. J Nucl Med 46:608–613
Vanel D, Bittoun J, Tardivon A (1998) A MRI of bone metastases. Eur Radiol 8:1345–1351
Schweitzer ME, Levine C, Mitchell DG, Gannon FH, Gomelia LG (1993) Bull’s eyes and halos: useful MR discriminators of osseous metastases. Radiology 188:249–252
Beggs AD, Hain SF, Curran KM, O’Doherty MJ (2002) FDG-PET as a “metabolic biopsy” tool in non-lung lesions with indeterminate biopsy. Eur J Nucl Med Mol Imaging 29:542–546
Groves AM, Beadsmoore CJ, Cheow HK, Kottekkattu KB, Courtney HM, Kaptoge S et al (2006) Can 16-detector multislice CT exclude skeletal lesions during tumour staging? Implications for the cancer patient. Eur Radiol 10:1–8
Layer G, Steudel A, Schueller H et al (1999) MRI to detect bone marrow metastases in the initial staging of small cell lung carcinoma and breast carcinoma. Cancer 85:1004–1009
Ohta M, Tokuda Y, Suzuki Y et al (2001) Whole body PET fort the evaluation of bony metastases in patients with breast cance: comparison with 99 Tcm-MDP bone scintigraphy. Nucl Med Commun 22:875–879
Moon DH, Maddahi J, Silverman DH et al (1998) Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 39:431–435
Marom EM, Mc Addams HP, Erasmus JJ et al (1999) Staging non-small cell lung cancer with whole-body PET. Radiology 212:803–809
Metser U, Lerman H, Blank A, Lievshitz G, Bokstein F, Even-Sapir E (2003) Malignant involvement of the spine: assessment by 18FDG-PET-CT. J Nucl Med 45:297–384
Hany TF, Steinert HC, Goerres WG, Buck A, von Schultheiss GK (2002) PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 225:575–581
Rosenbaum SJ, Lind T, Antoch G, Bockisch A (2005) False-positive FDG-PET uptake—the role of PET/CT. Eur Radiol 17:1–12
Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J et al (2003) Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290:3199–3206
Gallowitsch HJ, Kresnik E, Gasser J et al (2003) F-18 fluorodeoxyglucose positron-emission tomography ion the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol 38:250–256
Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I (1998) Detection of bone metastases in breast cancer by 18FDG-PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 16:3375–3379
Krishnamurthy GT, Tubis M, Hiss J, Blahd WH (1977) Distribution pattern of metastatic bone disease. JAMA 237:837–842
Perrin-Resche I, Bizais Y, Buhe T, Fiche M (1993) How iliac crest bone marrow biopsy compare with imaging in the detection of bone metastases in small cell lung cancer? Eur J Nucl Med 20:420–425
Haubold-Reuter BG, Duewell S, Schilcher BR, Marincek B, v Schulthess GK (1993) The value of bone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumors: a prospective study. Eur J Nucl Med 20:1063–1069
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schmidt, G.P., Schoenberg, S.O., Schmid, R. et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 17, 939–949 (2007). https://doi.org/10.1007/s00330-006-0361-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-006-0361-8